Fundraising Fox
iBio
NASDAQ: IBIOSan Diego, US · Founded 2008 · Delaware corporation · 59 employees on LinkedIn
Find your way into iBio
1,123 people in our graph can introduce you to the iBio team.
Sign up to see every warm intro you have to iBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the iBio team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
iBio is a biopharmaceutical company with leadership experienced in drug discovery, development, and clinical operations across multiple therapeutic areas. The company appears to focus on innovative therapeutics and biologics development.
Founders & leadership
FD
Felipe DuranChief Financial OfficerFelipe Duran is an executive officer at iBio with extensive experience in financial strategy and operations within biopharmaceutical organizations, including SEC reporting, capital raising, and strategic planning across global markets.
MB
Marc BanjakChief Legal OfficerHe has extensive experience in legal operations across medical device and pharmaceutical sectors, with expertise in contract negotiation and regulatory compliance.
TR
Terence RyanChief Scientific Officer2010–2019Chief Scientific Officer of iBio, Terence Ryan has experience managing cross-functional teams in drug discovery, with expertise spanning biomarker identification, systems biology, recombinant protein production, and the integration of omics technologies and machine learning in translational research.
RK
Robert KayExecutive Chairman and Chief Executive Officer
MG
Mark GiannoneChief Financial Officer
RE
Robert ErwinPresident
MC
Mr. Clark
MB
Mr. Banjak
DB
Dr. Brenner
MB
Martin BrennerCEO & CSOMartin Brenner is Chief Executive Officer and Chief Scientific Officer of iBio, a biopharmaceutical company focused on antibody therapeutics for obesity and cardiometabolic disease. He previously held leadership roles at Merck, AstraZeneca, Eli Lilly, Pfizer, and Pfenex, with expertise in drug discovery, development, and translational science across multiple therapeutic modalities.
Board
AK
Alexandra KroptovaBoard director
Reported raises · per SEC filings
Form D private placements$54.3M disclosed across 4 of 8 rounds · 1900–2026
▶$26MraisedJan 2026 · 7 investors · BiotechnologyRule 506(b)
▶$26MraisedJan 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ArkowitzDirector
- William ClarkDirector
- Martin A. BrennerExecutive Officer, Director
- Antonio ParadaDirector
- Marc BanjakExecutive Officer
- Evert ShimmelpenninkDirector
- Felipe DuranExecutive Officer
- Alexandra KropotovaDirector
- Gary SenderDirector
- Offering amount
- $26M
- Amount sold
- $26M
- Sales commissions
- $1.6M
- Placement agents
- Oppenheimer & Co. Inc., LifeSci Capital LLC, Leerink Partners LLC
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedMay 2025 · 5 investors · BiotechnologyRule 506(b)
▶$11.1MraisedMay 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Felipe DuranExecutive Officer
- Marc BanjakExecutive Officer
- Alexandra KroptovaDirector
- Gary SenderDirector
- David ArkowitzDirector
- Martin A. BrennerExecutive Officer, Director
- William ClarkDirector
- Antonio ParadaDirector
- Evert ShimmelpenninkDirector
- Offering amount
- $11.1M
- Amount sold
- $11.1M
- Sales commissions
- $217K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.1MraisedApr 2024 · 8 investors · BiotechnologyRule 506(b)
▶$15.1MraisedApr 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Felipe DuranExecutive Officer
- Gary SendeDirector
- William ClarkDirector
- Martin BrennerExecutive Officer
- Linda ArmstrongDirector
- James HillDirector
- Evert ShimmelpenninkDirector
- Alexandra KropotovaDirector
- Offering amount
- $15.1M
- Amount sold
- $15.1M
- Sales commissions
- $794.1K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MofferedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$10MofferedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marc BanjakExecutive Officer
- Gary SenderDirector
- Martin BrennerExecutive Officer
- Linda ArmstrongDirector
- James HillDirector
- Alexandra KropotovaDirector
- Evert SchimmelpenninkDirector
- William ClarkDirector
- Felipe DuranExecutive Officer
- Offering amount
- $10M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedFeb 2016 · 1 investors · BiotechnologyRule 506(b)
▶$2.2MraisedFeb 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terence RyanExecutive Officer
- Robert KayExecutive Officer
- Mark GiannoneExecutive Officer
- Arthur ElliottDirector
- Glenn ChangDirector
- James HillDirector
- Philip RussellDirector
- John McKeyDirector
- Robert ErwinExecutive Officer
- Seymour FlugDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
IO BiotechIOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
Companies working in the same space as iBio.
In the news
Frequently asked questions
- What does iBio do?
- iBio is a biopharmaceutical company with leadership experienced in drug discovery, development, and clinical operations across multiple therapeutic areas. The company appears to focus on innovative therapeutics and biologics development.
- How much funding has iBio raised?
- iBio has disclosed $54.3M raised across 4 of its 8 known rounds.
- Where is iBio headquartered?
- iBio is headquartered in San Diego, US.